


Tetrabenazine Racemate

Chemical Properties

CAS No. :	718635-93-9
Formula:	C19H27NO3
Molecular Weight:	317.42
Storage:	Store at low temperature Powder: -20°C for 3 years In solvent: -80°C for 1 year <i>Actual storage temperature shall be subject to the COA.</i>



Biological Description

Description	Tetrabenazine Racemate (Rubigen) is a selective and reversible inhibitor of vesicular monoamine transporter-2 (VMAT-2). Tetrabenazine Racemate blocks neurotransmitter uptake into adrenergic storage vesicles and has been used as a high-affinity label for the vesicle transport system.
Targets(IC50)	Monoamine Transporter
In vivo	BMS-663068 has good antiviral activity in subjects infected with virus shown to be susceptible (IC50, <100 nM) to the agent[1].

Solubility Information

Solubility	DMSO: 55 mg/mL (173.27 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (6.3 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	3.1504 mL	15.752 mL	31.504 mL
5 mM	0.6301 mL	3.1504 mL	6.3008 mL
10 mM	0.315 mL	1.5752 mL	3.1504 mL
50 mM	0.063 mL	0.315 mL	0.6301 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Jankovic, J. and J. Beach, Long-term effects of tetrabenazine in hyperkinetic movement disorders. *Neurology*, 1997. 48(2): p. 358-62.

Kenney, C., C. Hunter, and J. Jankovic, Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. *Mov Disord*, 2007. 22(2): p. 193-7.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481